ICON will open an office in Manila, Philippines, further expanding its footprint in the Asia-Pacific region. The company also recently expanded its operations in Seoul, Korea and moved its Central Laboratories to a larger facility in Singapore.

“With over 800 employees in 14 Asia-Pac countries and 13 years of successful operations in the region, Asia-Pacific is a key market for ICON,” commented Peter Gray, chief executive officer at ICON. “Philippines’ large population, coupled with the country’s well-established network of hospitals, physicians and investigators has made it an attractive location for our clients, and one which we have supported for a number of years through home-based employees. Investing in local support and infrastructure through the office in Manila will ensure that we can support future client demand as they increasingly look to include Asia in their drug development programs.”

ICON conducts a wide range of clinical studies across all therapeutic areas in Asia-Pacific, with a particular focus on managing oncology, cardiovascular, CNS and metabolic disorder trials in the region. Current studies range from small local trials to pan-Asia-Pacific and large global programs, supported by its central labs in Singapore and Bangalore, India.

News from our sister sites